Ginegar 2025: Sales Held Up, but Cash Tightened and India Is Still Not Closed

Getting to Know the Company

At first glance, Ginegar looks like a local agricultural plastics producer. That is too narrow. In practice, this is a global group with two very different engines under one roof: agricultural films and nets on one side, and technical films for industry, infrastructure, construction, and other applications on the other. In 2025, agriculture still accounted for 68% of sales, but it no longer carried most of the segment profit. Profitability was increasingly carried by the technical segment, especially the Italian Flextech operation.

That is the heart of the story. A superficial read sees a company that lifted revenue to NIS 628.3 million, trades at roughly NIS 108 million of market value, and still reports NIS 193.1 million of equity. It is easy to jump from there to a cheap-on-paper conclusion. That is the wrong filter. The real question is not whether Ginegar has revenue and equity. The real question is how much of that business quality survives the trip through inventory, receivables, short-term credit, and ongoing expansion spending.

What is working now? The business itself did not break. Sales were stable, the technical segment improved, there is no single customer dependency above 10% of revenue, and the company still complies with its financial covenants. What is still messy? Operating cash flow fell to negative NIS 17.4 million, short-term bank credit jumped to NIS 121.6 million, and the fourth quarter already ended with a net loss. In other words, the active bottleneck is no longer demand. It is cash conversion.

The story matters now because Ginegar is trying to widen its international footprint at exactly the moment when the balance sheet became more demanding. Agriplast in India has not yet closed, the Indian contract-manufacturer deal is still non-binding, and Mexico is still a strategic project rather than an earnings contributor. For the read to improve over the next 2 to 4 quarters, the company needs to show three things at once: better agricultural margins, a stop to working-capital expansion, and progress in India without another leg up in short-term funding.

Quick 2025 economic map:

Customer diversification supports resilience, but it does not change the fact that this is a business that lives or dies on inventory discipline, receivables management, and timely price updates. That is why the right way to read Ginegar is not “how much did it sell,” but “how much of those sales still reaches shareholders as usable cash.”

The company details 428 employees across the main units it breaks out in Israel, Brazil, Italy, Spain, the US, and Ginegar South. This is not a single-site factory story. It is a distributed industrial and commercial platform, which also means more moving parts in working capital, FX exposure, inventory, and execution.

Events and Triggers

The first trigger: Agriplast. In September 2025, Ginegar India signed binding agreements to increase its stake in Agriplast from 25% to 55% for roughly $3.7 million. This matters because Agriplast is not only an investment. It is also one of the group’s distribution channels in India. During March 2026, the remaining consideration was deposited into designated accounts in India, but by late March 2026 the company was still waiting for final regulatory approvals. That means the market can already see a real path to deeper control in India, but not a closed outcome yet.

The second trigger: the Indian contract manufacturer. In September 2025, Ginegar India signed a non-binding memorandum of understanding to acquire up to 60% of the exclusive Indian contractor that manufactures its products. The structure includes about $3.75 million of consideration, understandings regarding a long-term land lease for the plant site, and a new production line. Strategically, this is potentially bigger than the accounting line. It could turn India from a stronger distribution presence into an actual local control platform. But as of late March 2026 there was still no certainty that binding agreements would be signed or that the transaction would close.

The third trigger: Mexico. In November 2025, the company signed an agreement to establish a joint venture in Mexico in which it will hold 50.1%, aimed at marketing and selling agricultural films in Mexico and North America. The model also includes a 5-year production agreement with the local partner. The strategic logic is clear: better customer proximity, shorter logistics, and less reliance on exports from Israel or Italy. For now, though, this is still future shape rather than 2025 earnings.

The fourth trigger: the US tariff backdrop and supply-chain instability. The company recorded roughly NIS 3.2 million of tariff expense in 2025 on products imported into the US, including an unusual retroactive demand of around $142 thousand that is being appealed. The good news is that agricultural input products imported from Israel into the US have been exempt from customs duties since August 2025. The less comforting part is that products made in Brazil and Italy were still subject to tariffs, and the company does not expect similar relief for industrial products manufactured mainly in Italy.

The fifth trigger: the opening of 2026. The company describes sharp increases in raw-material prices, tighter polymer supply, higher sea-freight costs, and higher energy costs tied to the geopolitical backdrop in early 2026. At the same time, it says order flow and plant activity in Israel remain in line with plan. That is an important combination. Demand is not collapsing, but the operating environment is getting harder. That raises the importance of pricing discipline, inventory management, and commercial terms.

Efficiency, Profitability and Competition

The most interesting 2025 data point is not that revenue rose by 1.2%. The real point is that the company sold more and earned less. Gross profit fell from NIS 121.6 million to NIS 113.2 million, gross margin slipped from 19.6% to 18.0%, and operating profit from regular activity declined from NIS 28.8 million to NIS 23.8 million. That is not a demand story alone. It is a cost, mix, and commercial-quality story.

The technical segment is already carrying the earnings load

The technical segment generated NIS 199.1 million of revenue in 2025, basically flat versus 2024, but segment result rose to NIS 34.9 million, up about 14.8%. Agriculture, by contrast, rose modestly to NIS 429.2 million of revenue, but segment result fell to NIS 19.3 million, down about 28.5%. The implication is straightforward: 32% of revenue generated roughly 64% of total segment result.

That does not mean agriculture stopped being the core business. It does mean the group became more dependent on a profit engine centered on technical films, sacks, bags, and covers, especially through Flextech. The disclosed advance payments for machinery at the Italian production site, roughly NIS 10 million, reinforce that reading.

Agriculture sold more, but not on the same quality

Agriculture is still the volume heart of the company, but the 2025 quality was weaker. Management itself points to several drivers: roughly NIS 3.3 million of net customs expense on exports to the US, a full year of Ginegar South whose sales include trading activity rather than local manufacturing, and shifts in product and geographic mix. Those are not background items. They mean the top line held up, but part of that resilience came at a cost lower down the income statement.

That matters especially because the volume growth was real. The company reports roughly 3% growth in kilograms and roughly 7% growth in square meters. And yet profit still weakened. In other words, growth was not enough by itself. The commercial terms and cost environment behind that growth mattered more than the headline volume.

The fourth quarter broke the illusion

Fourth-quarter revenue was almost unchanged at NIS 142.6 million versus NIS 142.4 million a year earlier. But gross profit dropped from NIS 31.8 million to NIS 26.7 million, gross margin fell from 22.3% to 18.7%, operating profit fell from NIS 7.1 million to NIS 4.6 million, and the quarter ended with a NIS 0.5 million net loss versus a NIS 2.5 million profit a year earlier.

That is the near-term signal the market should carry forward. It says 2026 is not opening from a clean base. If agriculture keeps losing margin quality, the technical segment will not be enough to offset all of the funding pressure on its own.

Competition matters less than pricing quality

There is no single major customer holding the company together. Quite the opposite. No customer exceeded 10% of revenue, and channel dependence is also not framed as critical. That means the main competitive question is not concentration risk. It is whether Ginegar can keep passing through costs fast enough when raw materials, logistics, and tariffs move quickly.

Cash Flow, Debt and Capital Structure

This is where the critical 2025 issue sits. On an all-in cash flexibility basis, this was not a year of cash generation. It was a year of keeping activity moving by changing the funding structure. Operating cash flow fell to negative NIS 17.4 million, investing cash flow was negative NIS 30.0 million, the company paid NIS 15 million of dividends, repaid NIS 36.5 million of long-term debt, and paid NIS 6.3 million of lease liabilities. Without an NIS 86.4 million increase in short-term bank credit and NIS 18.3 million of new long-term loans, the cash picture would have been far more exposed.

The pressure moved from long to short

The balance sheet tells that story very clearly. Short-term bank credit jumped from NIS 35.3 million to NIS 121.6 million. Current maturities of long-term debt edged down to NIS 32.9 million, and non-current bank and other loans fell from NIS 111.0 million to NIS 89.9 million. So the issue is not just more debt. It is also a shorter debt structure.

This does not automatically mean distress. The company explicitly says it chose not to take new long-term loans or extend existing ones during the period because it expected lower interest rates and instead funded more of the business with short-term credit. That choice has logic if rates move in your favor. But it also has a cost: less visibility, more dependence on rolling facilities, and higher sensitivity to working-capital swings.

Working capital absorbed the year

Working capital of NIS 183 million sounds like a buffer until you look at what is inside it. Inventory stood at NIS 168.8 million, receivables at NIS 186.2 million, other receivables at NIS 22.0 million, and payables fell to NIS 125.2 million. Operating working capital, inventory plus receivables minus payables, rose from NIS 195.5 million to NIS 229.8 million.

From a cash perspective, those are the numbers that matter most: NIS 14.6 million went into receivables, NIS 2.8 million into other receivables, NIS 5.6 million into inventory, and NIS 16.3 million went out through lower supplier balances. That is the main reason the company moved from positive NIS 16.6 million of operating cash flow in 2024 to negative NIS 17.4 million in 2025.

Inventory is both moat and risk

Inventory did not explode versus 2024. It even declined slightly to NIS 168.8 million. But it is still huge relative to the balance sheet, and the auditors explicitly flagged it as a key audit matter. After provisions, inventory still represents around 25% of total assets. That is a heavy position for this kind of business, especially when the company also keeps safety stock of raw materials and reports around 120 days of finished-goods inventory on average.

That is not automatically negative. Safety stock is also an operating advantage in a disrupted supply environment. The company even notes that the policy allowed it to keep production running without stoppages in difficult periods. But the same operating edge is also a balance-sheet risk because it needs funding, depends on valid net realizable values, and is exposed to fast changes in input prices.

There is no covenant crisis, but there is not unlimited room either

It is important to be precise here. Ginegar is not in covenant trouble. As of December 31, 2025 it complied with all its financial tests: tangible equity to tangible assets of 31.6% versus a 25% minimum, tangible equity of NIS 183 million versus a NIS 141 million floor, net bank debt to EBITDA of 3.1 versus a ceiling of 5, and short-term credit net of cash to operating working capital of 0.5 versus a ceiling of 0.8.

That is the balancing fact in the story. There is no immediate covenant wall. But it would also be wrong to read 2025 as fully comfortable. Covenant headroom still depends on inventory holding value, receivables rotating normally, and operating earnings staying intact. If one of those pillars weakens, the margin of safety will look a lot less generous.

Forecast and Forward View

Finding one: this is no longer mainly a growth story. It is now a quality-of-growth story. Sales can rise while profit and cash fall.

Finding two: the technical segment has become the group’s main profit engine. If it holds up, it can offset part of the agricultural weakness. If it weakens too, the picture deteriorates much faster than consolidated revenue suggests.

Finding three: India is a serious strategic option, but still not an operating fact. The market can start pricing future control through Agriplast and the contractor path, but until approvals arrive and the structure is settled, that upside still comes with cost and uncertainty.

Finding four: the fourth quarter already flashed the warning. When revenue is flat and earnings swing into loss, easier raw materials or lower rates cannot be assumed to solve the problem on their own.

For 2026, this does not look like a breakout year. It looks like a proof year. The company needs to prove it can keep volume, price well enough through a more expensive input environment, and bring operating cash flow back into positive territory without relying even more heavily on short-term funding.

The optimistic read says 2025 was mainly about timing: choosing short funding while waiting for better rates, continuing investment in capacity, and advancing international moves that have not yet fully translated into earnings. The cautious read says the company hit exactly the point where international growth demands more inventory, more receivables, and more balance-sheet support, which means less room for execution mistakes.

What has to happen over the next 2 to 4 quarters for the story to improve is fairly clear. First, agriculture needs margin recovery, not just revenue stability. Second, working capital needs to stop growing faster than the business. Third, Agriplast needs to close and start making operational sense. Fourth, the technical segment needs to preserve profitability even if Europe and raw-material conditions stay volatile.

Risks

The first risk is inventory and working capital risk. When inventory is a quarter of the balance sheet, the question is not only whether it can be sold, but how fast it can be sold, how it ages, how pricing behaves, and whether the recorded value is still robust. Safety stock is an operating strength, but it is not cash.

The second risk is funding and liquidity structure. As of year-end 2025, the first-year contractual liability stack stood at NIS 314.7 million, including NIS 160.2 million of bank and other loans, NIS 125.2 million of supplier liabilities, and NIS 10.1 million of lease liabilities. That does not mean the whole amount is a hard wall at once, because part of it rolls operationally. It does mean the business depends heavily on banks, suppliers, and normal inventory turnover all working together.

The third risk is FX. At year-end 2025 the company carried excess monetary liabilities over assets of NIS 59.0 million in US dollars and NIS 52.2 million in euros, partly offset by net asset positions in Indian rupees, Brazilian reais, and Moroccan dirhams. The company hedges from time to time, but this is not trivial exposure. When net profit is small, FX moves matter more.

The fourth risk is India execution. Agriplast still needs final approval, the contract-manufacturer deal is still non-binding, and together the two moves could either create a real local control platform or require more capital before delivering real operating control.

The fifth risk is external cost pressure. US tariffs, freight costs, polymer prices, and energy costs all matter in exactly the kind of business where raw materials and logistics sit at the core of the cost structure. The company can reprice, but there is no evidence that it can pass through everything without friction.

Conclusions

Ginegar ends 2025 as a company whose operations are alive, whose customer base is diversified, and whose technical segment is actually improving. The problem is that the cash is not moving with the same quality, and the balance sheet is funding too much of the activity through short-term credit and heavy working capital. In the near term, the market is likely to focus less on sales growth and more on cash conversion, the Agriplast closing, and whether agricultural margins can stabilize.

Current thesis: Ginegar is now a business that still operates, but whose earnings and cash quality need to be re-proven.

What changed in this cycle is that the key question is no longer whether the company can grow. It is whether it can grow without diluting margin quality and without leaning more heavily on short-term debt.

Counter-thesis: 2025 may prove to be mostly about timing, investment, and a temporary funding mix choice. If Agriplast closes, agriculture reprices better, and the technical segment stays strong, the year could later look more like a bridge than the start of structural deterioration.

What could change the market reading over the short to medium term is quite visible: Agriplast closing, a return to positive operating cash flow, lower short-term credit, and better agricultural margins in the next reporting windows.

Why does this matter? Because the gap between market value and book equity can look attractive on paper, but as long as that equity sits inside inventory, receivables, and short-term funding needs, not all of the created value is truly accessible to common shareholders.

Over the next 2 to 4 quarters, the thesis strengthens if Ginegar shows better cash conversion, stable technical-segment profitability, and closed-loop progress in India. It weakens if working capital keeps expanding, if the weak fourth quarter turns out to be the start of a trend, or if the international projects demand more capital before producing real operating control.